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ABSTRACT
Background The burden of uncontrolled hypertension 
in sub- Saharan Africa (SSA) is high and hypertension is 
known to coexist with other chronic diseases such as 
kidney disease, diabetes among others. This is the first 
systematic review and meta- analysis to determine the 
burden of uncontrolled hypertension among patients with 
comorbidities in SSA.
Methods A comprehensive search was conducted on 
MEDLINE, Excerpta Medica Database (Embase) and 
Web of Science to identify all relevant articles published 
between 1 January 2000 and 17 June 2021. We included 
studies that reported on the prevalence of uncontrolled 
hypertension among people in SSA who report taking 
antihypertensive treatment and have another chronic 
condition. A random- effects meta- analysis was performed 
to obtain the pooled estimate of the prevalence of 
uncontrolled hypertension among patients with comorbid 
conditions while on treatment across studies in SSA.
Results In all, 20 articles were included for meta- 
analyses. Eleven articles were among diabetic patients, 
five articles were among patients with HIV, two were 
among patients with stroke while chronic kidney disease 
and atrial fibrillation had one article each. The pooled 
prevalence of uncontrolled hypertension among patients 
with comorbidities was 78.6% (95% CI 71.1% to 85.3%); 
I² 95.9%, varying from 73.1% in patients with stroke 
to 100.0% in patients with atrial fibrillation. Subgroup 
analysis showed differences in uncontrolled hypertension 
prevalence by various study- level characteristics
Conclusion This study suggests a high burden of 
uncontrolled hypertension in people with comorbidities 
in SSA. Strategies to improve the control of hypertension 
among people with comorbidities are needed.
PROSPERO registration number CRD42019108218.
INTRODUCTION
Hypertension is an important risk factor 
for cardiovascular diseases and a leading 
contributor to death globally.1 An estimated 
1.4 billion people have hypertension globally 
with three quarter (75%) of this population 
living in low and middle- income countries.2 3 
Worldwide trend analysis based on a large data 
set from multiple studies conducted between 
1975 and 2015 in 200 countries showed no 
change in global mean blood pressure, but a 
substantial downward trend in high- income 
countries and a rise in low and middle- income 
countries.4 Levels of hypertension awareness, 
treatment and control improved by 2.9% in 
high- income countries while in low–middle- 
income countries, negligible improvements 
in awareness, treatment and control were 
observed.3 4 Africa is one of the regions in the 
world with the highest rates of uncontrolled 
blood pressure.5 In a systematic review and 
meta- analysis on hypertension in sub- Saharan 
Africa (SSA), Ataklte et al6 reported a (93%) 
high prevalence of uncontrolled hyperten-
sion (UHTN).
Hypertension often coexists with comorbid-
ities such as chronic kidney disease, diabetes 
and hypercholesterolemia among others.7–10 
These comorbidities could explain part of 
the inadequacy in blood pressure control. 
Some studies conducted in Europe and the 
Strengths and limitations of this study
 ► A published comprehensive protocol was used to 
identify all available evidence without language 
restriction, reporting in accordance with Preferred 
Reporting Items for Systematic reviews and Meta- 
Analyses guidelines, search using multiple electron-
ic databases, searching grey literature, contacting 
experts in the field for additional data sources to 
reduce study selection bias and heterogeneity test 
by subgroup analyses and sensitivity analyses.
 ► The prevalence of uncontrolled hypertension in some 
comorbidities such as atrial fibrillation and chronic 
kidney disease was reported in single studies.
 ► Most of the studies included in the meta- analysis 
were hospital- based studies that used non- random 
sampling procedures.
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USA found that patients with diabetes mellitus had a 
significantly increased risk of uncontrolled blood pres-
sure.11 12 Another study conducted in the UK has shown 
that achieving optimal blood pressure control in patients 
with hypertension and type 2 diabetes produces an 
important decrease in the risks associated with diabetes.13
In recent years, public health efforts to promote 
prevention, awareness and treatment of hypertension 
in SSA have intensified,14–17 but hypertension control 
remains low.18–22 Despite several studies conducted on 
UHTN in people with comorbidities, pooled estimations 
of the burden are not available for comorbidities such as 
diabetes, dyslipidaemia, stroke, HIV, obesity atrial fibrilla-
tion. From a clinical perspective, it is important to under-
stand why patients on treatment are not attaining optimal 
blood control and whether their pre- existing comorbid-
ities contribute to the lack of control of blood pressure. 
Therefore, to inform policy, practice and the develop-
ment of guidelines for hypertension for integrated care 
among patients with comorbid conditions, it is critical to 
understand the burden of UHTN in people with comor-
bidities. The purpose of this review is to summarise the 
evidence on and estimate the prevalence of UHTN in 
patients with comorbidities in SSA and to explore factors 
associated with UHTN in people with comorbidities.
METHODS
Protocol and registration
The protocol for this systemic review and meta- analysis 
was registered on the International Prospective Register 
of Systematic Reviews and published.23 The reporting 
was done according to the Preferred Reporting Items for 
Systematic reviews and Meta- Analyses (PRISMA) Proto-
cols guidelines.24
Search strategy
We systematically searched MEDLINE via Ovid, Excerpta 
Medica Database (Embase) and Web of Science from 
1 January 2000 to 17 June 2021. The search strategy 
included the following relevant terms: uncontrolled hyper-
tension, hypertension, uncontrolled blood pressure, high blood 
pressure, a list of comorbidities and sub- Saharan Africa (detailed 
search strategy list is attached as supplement (online supple-
mental file S1). Additionally, the reference lists of the 
included studies were reviewed to identify other relevant 
studies.
Eligibility criteria
Studies were included if (1) they provided primary data 
on the prevalence of hypertension in accordance with the 
seventh report of the Joint National Committee among 
those who reported taking antihypertensive treatment 
and had a comorbid condition, (2) participants had been 
diagnosed with one of the comorbidities of interest—
diabetes, dyslipidaemia, obesity, chronic kidney disease, 
stroke or transient ischaemic attack, coronary heart 
disease, heart failure, peripheral vascular disease, atrial 
fibrillation, depression and HIV (online supplemental 
table S1), (3) participants were 15 and above years, (4) 
the study was published in any language and (5) the 
study was conducted in an SSA. The following types of 
study designs were excluded: (1) case–control studies, 
commentaries, editorials, letters, qualitative studies and 
systematic reviews; (2) studies that included hypertension 
prevalence but did not report on the prevalence of hyper-
tension among those on antihypertensive medication and 
(3) studies of pregnancy- related hypertension.
Study selection
Two researchers independently screened the titles and 
abstracts (SFM and MSA). Two researchers (SFM and 
MSA) also assessed full- text reviews of the articles inde-
pendently for final inclusion. The reference lists of poten-
tially relevant publications were manually searched for 
additional publications. Disagreements were resolved by 
consensus. For multinational studies, data were separated 
to show the estimate at the country level.
Data items and collection process
SFM and MSA independently screened the full texts of 
included studies. SFM extracted data from the selected 
studies and MSA checked the data for accuracy. A stan-
dardised data extraction table was created (table 1) and 
included the following data from all eligible articles: first 
author name, year of publication, language, country of 
the study, study design, sample size, study period, study 
setting, sampling method, the timing of data collection, 
data source, use of comorbidity- specific hypertension 
control cut- off, male proportion, age of participants 
(mean or median), type of comorbidity (diabetes, stroke, 
HIV, chronic kidney disease, atrial fibrillation) and main 
outcome of interest UHTN proportion or the data to 
cumpute it.
Risk of bias in individual studies
A tool developed by Hoy et al25 for prevalence studies was 
adapted and used to assess the methodological quality of 
included studies by evaluating the extent to which they 
addressed bias in nine areas of internal and external 
validity (online supplemental table S2). Each of the 
nine areas was scored 1 if yes (high quality) and 0 if no 
(poor quality), and a total quality score was calculated by 
summing the individual scores. Total scores ranged from 
0 to 9, with higher scores indicating higher quality. Studies 
were then classified as having a low (>8), moderate (6–8) 
or high (≤5) risk of bias. Two researchers (SFM and MKM) 
independently assessed each of the included publications 
and disagreements were resolved through discussion.
Patient and public involvement
This research was done without patient involvement. 
There was no involvement of patients or members of the 
public in the design, or conduct, or reporting or dissemi-
nation plans of this research.
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Synthesis of results
The statistical approach used in this meta- analysis 
followed the study protocol.23 Crude numerators and 
denominators from the individual studies were used to 
recalculate the study- specific unadjusted prevalence 
estimates. Variances of the study- specific estimates were 
stabilised using the double arcsine transformation to 
minimise the effect of studies with very small or very 
large prevalence estimates on the overall estimate (16), 
and then a random- effects meta- analysis was performed 
(17) to determine the pooled estimate of the prevalence 
of UHTN among patients with comorbidities overall and 
also among people with diabetes, HIV and stroke sepa-
rately while on antihypertensive treatment across the 
included studies in SSA. Prevalence estimates were also 
summarised by comorbidities, publication year, sample 
size, study setting, sampling, risk of bias, gender propor-
tionmean age and geographic regions.
Heterogeneity was explored using Cochrane’s Q and 
quantified by I² statistics.26 27 Subgroup analyses were 
performed based on the following: gender proportion 
of participants, patient comorbidities, study design, study 
setting, sample size, use of recommended comorbidity- 
specific blood pressure control cut- offs, countries, regions 
(Eastern, Western, Central, and Southern Africa) and by 
gross national income (GNI) were performed to identify 
the possible sources of heterogeneity. Sensitivity analyses 
were performed to assess the robustness of the findings 
by excluding studies with a high risk of bias.
Funnel plots and Egger asymmetry test were used to 
assess publication bias, with p< 0.10 considered to be 
statistically significant for publication bias.28 Inter- rater 
agreements between the researchers involved in study 
inclusion and those involved in the identification of risk 
of bias were assessed using κ Cohen’s coefficient (20).
All analyses were performed using ‘metaprop’ routine 
using StataSE V.16 (StataCorp LLC).
RESULTS
Study selection
From the electronic database search, 8492 records 
were identified. An additional 35 articles were identi-
fied through reference tracing and from other sources. 
After duplicate removal, 5610 remained for the title 
and abstract screening. After screening, we found 5085 
records to be irrelevant and excluded them. The full texts 
of 525 articles and reports were retrieved and assessed for 
eligibility, resulting in the inclusion of 20 studies for the 
meta- analysis (figure 1). The inter- rater agreement for 
study selection was 0.77.
Study characteristics
Table 1 and online supplemental table S3 provide detailed 
information on the included studies. In total, 3510 partic-
ipants were included across 20 studies. Most of the studies 
were cross- sectional (19, 95%), in English (19, 95%), 
hospital- based (12, 60%), used consecutive sampling 
(16, 80%) and prospectively collected data (14, 70%). 
The mean (SD) participant age from the 20 studies29–48 
providing this information was 56.8 (0.12) years. Study 
sample sizes ranged from 10 to 567 participants. The 
proportion of male participants in the included studies 
was reported in all studies and it ranged from 21.4% to 
60.9%.29–48 Of the included studies, 1130–32 34 35 39–43 46 
reported on diabetes, five36 38 44 47 48 reported on HIV, 
two29 45 reported on stroke and one each reported on 
chronic kidney disease33 and atrial fibrillation.37 None of 
the included studies reported on obesity, dyslipidaemia, 
coronary heart disease, heart failure, peripheral heart 
disease and depression.
Risk of bias assessment
The risk of bias was assessed in all included studies 
of the 20 included studies. Most studies were cate-
gorised as having some concern for bias with two 
(10%)37 46 studies being deemed to have high risk of bias. 
Two studies32 44 (11.1%) had a moderate risk of bias, while 
16 studies29–31 33–36 38–43 45 47 48 (80%) had a low risk of bias. 
The inter- rater agreement for the risk of bias assessment 
was 0.65. Additional details on the domains assessed are 
included in the risk of bias summary table in the online 
supplemental table S2.
Prevalence of UHTN among patients with comorbidities
Twenty publications reported on UHTN among patients 
with comorbidities (table 1). The majority of the 
studies were from South Africa (8, 40%).29 31 36 37 40–43 
Uganda,33 38 Nigeria,32 45 Malawi35 44 Ethiopia30 47 and 
Tanzania,39 48 had two (10%) studies each while Senegal46 
and Cameroon34 had one study (5%) each. The reported 
Figure 1 Study selection flow diagram.
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prevalence of UHTN among people with comorbidities 
ranged from 41.8% (95% CI 32.2% to 52.0%) in Uganda 
to 100.0% (95% CI 98.1% to 100.0%) in South Africa. 
The pooled UHTN prevalence estimate in patients with 
comorbidities from the random- effects meta- analysis was 
78.6% (95% CI 71.1% to 85.3%). Substantial hetero-
geneity (I2=95.9%; p<0.0001) existed in the included 
studies (table 2). Absence of publication bias is suggested 




studies Number of participants I2 (95% CI) Pheterogeneneity
Overall 78.6 (67.9 to 83.0) 20 3510 96.1 <0.0001
By comorbidity
  Atrial fibrillation 100.0 (98.1 to 100.0) 1 198 – –
  Chronic kidney disease 75.9 (69.4 to 81.4) 1 191 – –
  Diabetes 74.5 (67.1 to 81.3) 11 2399 93.1 <0.001
  HIV 83.7 (56.0 to 99.5) 5 221 94.4 <0.001
  Stroke 73.1 (69.1 to 76.9) 2 501 – –
By region
  Eastern 80.8 (64.6 to 93.1) 6 772 94.7 <0.001
  Western 69.8 (57.0 to 81.2) 3 415 – –
  Central 79.6 (70.6 to 86.4) 1 98 – –
  Southern 79.8 (68.1 to 89.4) 10 2225 97.3 <0.001
By risk of bias
  Low 76.4 (69.3 to 82.8) 16 3146 94.4 <0.001
  Moderate 72.0 (63.3 to 80.0) 2 114 – –
  High 99.0 (97.1 to 100.0) 2 250 – –
By study size
  Small studies 77.6 (66.0 to 87.4) 10 565 88.6 <0.001
  Large studies 79.5 (69.0 to 83.0) 10 2945 97.7 <0.001
By period of publication
  Before 2015 79.4 (66.5 to 89.9) 10 1851 97.3 <0.001
  After 2015 77.3 (68.0 to 85.4) 10 1659 93.1 <0.001
By gender proportion
  More females 75.4 (67.6 to 82.5) 14 2140 92.5 <0.001
  More males 84.1 (69.5 to 94.7) 6 1370 97.6 <0.001
By sampling
  Consecutive 76.1 (67.6 to 83.7) 18 2639 95.6 <0.001
  Random 64.5 (61.1 to 67.9) 2 784 – –
By setting
  Hospital 78.4 (69.8 to 86.0) 12 2548 95.3 <0.001
  Health centre 79.4 (60.7 to 93.4) 8 962 96.8 <0.001
By comorbidity HTN target
  Comorbidity target used 70.7 (61.3 to 79.2) 13 1776 93.3 <0.001
  Comorbidity target not 
used
83.0 (72.4 to 91.4) 7 1734 96.3 <0.001
By gross national Income
  Below SSA average 78.6 (68.2 to 87.4) 9 1179 91.9 <0.001
  Above SSA average 78.3 (66.1 to 88.4) 11 2331 97.3 <0.001
Pegger=0.381
SSA, sub- Saharan Africa.
 on D
ecem









pen: first published as 10.1136/bm






6 Mohamed SF, et al. BMJ Open 2021;11:e045880. doi:10.1136/bmjopen-2020-045880
Open access 
by the symmetrical visual inspection of the funnel plot, 
confirmed by the Egger’s test (p<0.001) (figure 2).
Subgroup analysis revealed differences in UHTN 
prevalence by comorbidity (figure 3). Adults with 
atrial fibrillation reported the highest UHTN estimate 
(100.0% (95% CI 98.1% to 100.0%)), followed by adults 
with HIV (83.7% (95% CI 56.0% to 99.5%)). The lowest 
pooled UHTN prevalence estimate was found in adults 
with stroke (73.1% (95% CI 69.1% to 76.9%)). Pooled 
UHTN prevalence differed by geographic regions; 
studies conducted in the Eastern, Southern and Central 
region reported higher prevalence’s (80.8% (95% CI 
64.6% to 93.1%)), (79.8% (95% CI 68.2% to 89.3%)) 
and (79.6% (95% CI 70.6% to 86.4%)), respectively, 
than studies conducted in the Western region (69.8% 
(95% CI 57.0% to 81.2%)). Prevalence varied by sample 
size; large studies reported a slightly higher prevalence 
(79.5% (95% CI 69.1% to 88.2%)) compared with small 
studies (77.6% (95% CI 66.0% to 87.4%)) (table 2). 
Studies that used the recomended hypertension control 
value for each comorbidity reported lower pooled 
prevalence of UHTN (75.8 (95% CI 66.4 to 84.1)) 
compared with those who did not use the recomemded 
comorbidity- specific blood pressure control value (83.0 
(95% CI 72.4 to 91.4)).
In the univariable analysis, heterogeneity was explained 
by being woman (11.3%), risk of bias (18.4%), by regions 
(15.8%), comorbidities (3.5%) and using target blood 
pressure (21.3%) (online supplemental table S4). 
However, only comorbidities and risk of bias were signif-
icant at 10%, and these were added to the multivariable 
meta- regression analysis. The results from the multivari-
able meta- regression were not statistically significant. 
Sensitivity analysis conducted by excluding studies that 
had high risk of bias from the analysis did not show any 
Figure 2 Funnel plot of the prevalence of uncontrolled 
hypertension in people with comorbidities in sub- Saharan 
Africa.
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influence on the robustness of the findings in the pooled 
analyses.
Sensitivity analysis done by excluding studies with high 
risk of bias from the analysis did not show any influence 
on the robustness of the findings in the pooled analysis.
Prevalence of UHTN among patients with diabetes
The prevalence of UHTN prevalence estimate 
among patients with diabetes was reported in 11 
studies,30–32 34 35 39–43 46 with a total of 2399 participants. 
UHTN prevalence in this group ranged from 54% (95% 
CI 50% to 58%) to 85% (95% CI 78% to 90%), with a 
pooled estimate of 74.5% (95% CI 67.1% to 81.3%) 
(table 2). Substantial heterogeneity (I2=93.1%; p<0.001) 
was observed in the included studies (figure 2). Publica-
tion bias was not evident from the visual inspection of the 
funnel plot (figure 4).
 Subgroup analysis revealed differences in UHTN 
prevalence among people with diabetes (table 3). There 
were differences noted by sample size; large studies 
reported a higher prevalence (75.5% (95% CI 67.1% to 
81.3%)) compared with small studies (73.3% (95% CI 
68.2% to 79.3%)) (table 2). Pooled UHTN prevalence 
differed by geographic regions; studies conducted in the 
Eastern reported the highest pooled prevalence (82.5% 
(95% CI 80.4% to 87.1%)) while studies conducted in the 
Southern region reported the lowest pooled prevalence 
(72.5% (95% CI 62.0% to 81.8%)). Gender differences 
were also noted; studies with more male participants 
had higher pooled prevalence (72.5% (95% CI 64.4% 
to 79.9%)) compared with studies with more female 
participants. Studies conducted after 2015 had higher 
pooled prevalence of UHTN among people with diabetes 
compared with studies conducted before 2015. Studies 
that used the recommended diabetes hypertension 
cut- off (BP <130/85 mm Hg) to define blood pressure 
control reported lower UHTN prevalences compared 
with those who did not use the recommended hyperten-
sion control value. Studies that had below the average 
SSA GNI reported a higher prevalence of UHTN (77.3 
(95% CI 69.7 to 84.2)) compared with studies with above 
the average SSA GNI (72.3 (95% CI 61.0 to 82.3)).
In the univariable analysis, the use of the recomended 
hypertension control value for diabetes explained the 
most of the heterogeneity (56.7%) observed while 
sampling explained 100% of the heterogeneity (online 
supplemental table S5). In the final multivariable model, 
the sampling method used was associated with UHTN 
and explained most of the heterogeneity.
DISCUSSION
To our knowledge, this is the first systematic review and 
meta- analysis on the pooled prevalence of UHTN among 
patients with comorbidities in SSA. Our findings indicate 
that more than three quarters of the hypertensive people 
with comorbidities have UHTN. These findings support 
the literature describing the challenges in controlling 
blood pressure among those on treatment and living with 
comorbidities while highlighting the fact that recognition 
of patient comorbidities should be a core aspect of the 
care and support offered to patients with hypertension.
The prevalence of UHTN varied with the type of 
comorbidity. The highest pooled UHTN prevalence esti-
mate (83.7%) was observed in people with HIV (83.7%), 
chronic kidney disease (75.9%) and diabetes (74.5%). 
A systematic review and meta- analysis on the prevalence 
of hypertension among people with HIV showed that 
about 25% of people with HIV had hypertension.49 Also, 
important to note is that the majority of people living with 
HIV are in SSA. Similarly, a UK study found reduced risk 
associated with diabetes in people who achieved optimal 
blood pressure.13 Another study conducted in Kenya 
found that 80% of diabetic patients from rural and semi-
urban areas had hypertension.50 Since hypertension is 
common among people with comorbidities, there is need 
to focus on integrated care for comorbidities and hyper-
tension. These findings support literature describing 
the challenge in blood pressure control among those on 
treatment and with comorbidities.
The high prevalence of UHTN in people with comor-
bidities is concerning and requires further understanding. 
There are several factors affecting UHTN among patients 
on treatment. Non- adherence to antihypertensive is an 
important cause of UHTN. A systematic review conducted 
by Abegaz et al found 45% of patients on antihypertensive 
were non- adherent to medications with a higher propor-
tion (84%) being among those with uncontrolled blood 
pressures.51 Barriers to adherence are mainly related 
to limited accessibility to medications, medication side 
effects, low perception of the risks involved with having 
uncontrolled blood pressure, out- of- pocket costs and pill 
burden due to comorbidities. Provider related factors 
also affect the UHTN rates. A study conducted by Rose 
et al concluded that inadequate treatment regimens 
are to blame for a majority of UHTN.8 Provider lack of 
adherence to hypertension guidelines in regards to dose 
Figure 4 Funnel plot of the prevalence of uncontrolled 
hypertension in people with diabetes in sub- Saharan Africa.
 on D
ecem









pen: first published as 10.1136/bm






8 Mohamed SF, et al. BMJ Open 2021;11:e045880. doi:10.1136/bmjopen-2020-045880
Open access 
escalation and use of multiple drug regimens are barrier 
to hypertension control. Chow et al revealed that the use 
of multiple drug regimens to treat hypertension was lower 
in low- income countries compared with the higher, upper 
middle or the lower middle- income countries.10
The prevalence of UHTN has declined significantly 
in studies published after 2015 compared with those 
published before 2015 probably because of adherence to 
the changing guidelines promoting tighter blood pres-
sure control for people with comorbidities. However, 
despite the observed decline, the prevalence of UHTN 
among people with comorbidities is very high and needs 
further research to understand the interventions that 
can reduce the UHTN rate, so it can be adapted in other 
countries.
Our findings have the potential to inform public 
health strategies to reduce the burden of UHTN in SSA. 
Addressing the barriers identified is essential in achieving 
optimal blood pressure levels. The WHO’s global target 
on hypertension control action plan recommends inte-
grated care programmes for the management of hyper-
tension and comorbidities, a recommendation supported 
by the results of the current study.1
Table 3 Meta- analysis results for the prevalence of uncontrolled hypertension in people with diabetes in sub- Saharan Africa
Prevalence (95% CI)
Number of 
studies Number of participants I2 (95% CI) Pheterogeneneity
Overall 74.5 (67.1 to 81.3) 11 2399 93.1 <0.001
By region
  Eastern 82.5 (78.8 to 85.9) 2 449 – –
  Western 75.0 (67.1 to 82.1) 2 131 – –
  Central 79.6 (70.6 to 86.4) 1 98 – –
  Southern 72.5 (62.0 to 81.8) 6 1721 94.9 <0.001
By risk of bias
  Low 74.2 (65.8 to 81.9) 9 2268 94.4 <0.001
  Moderate 70.9 (60.1 to 78.8) 1 79 – –
  High 80.8 (68.1 to 89.2) 1 52 – –
By study size
  Small studies 73.25 (66.8 to 79.3) 5 344 40.6 0.15
  Large studies 75.5 (64.82 to 84.8) 6 2055 96.4 <0.001
By period of publication
  Before 2015 72.9 (62.4 to 82.3) 4 1245 92.4 <0.001
  After 2015 78.0 (71.9 to 83.6) 7 1154 79.6 <0.001
By gender proportion
  More females 72.5 (64.4 to 79.9) 9 1919 92.2 <0.001
  More males 83.9 (80.4 to 87.1) 2 480 – –
By sampling
  Consecutive 76.7 (72.3 to 80.9) 9 1780 75.2 <0.001
  Random 54.1 (50.0 to 58.2) 1 567 – –
By setting
  Hospital 75.7 (66.0 to 84.3) 8 1825 94.9 <0.001
  Health centre 71.6 (61.5 to 80.8) 3 574 – –
By comorbidity HTN target
  Comorbidity target used 70.1 (57.4 to 81.5) 5 863 90.1 <0.001
  Comorbidity target not 
used
78.2 (73.1 to 82.9) 6 1536 79.3 <0.001
By gross national Income
  Below SSA average 77.3 (69.7 to 84.2) 5 852 81.1 <0.001
  Above SSA average 72.3 (61.0 to 82.3) 6 1547 94.9 <0.001
Pegger <0.001.
HTN, hypertension; SSA, sub- Saharan Africa.
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Strengths and limitations
Strengths of our systematic review and meta- analysis 
include the use of a published comprehensive protocol23 
to identify all available evidence without language restric-
tion, reporting in accordance with PRISMA guidelines, 
search using multiple electronic databases, searching grey 
literature, contacting experts in the field for additional 
data sources to reduce study selection bias and hetero-
geneity test by subgroup analyses and sensitivity analyses.
This study should, however, be interpreted in the 
context of the following limitations. First, it is important 
to note that control of hypertension among those on treat-
ment was not the main outcome of most of the included 
studies. Second, the prevalence of UHTN in some comor-
bidities such as atrial fibrillation and chronic kidney 
disease were reported in single studies probably because 
these conditions are understudied in SSA, thus limiting 
the generaliseability of such findings. Fourth, most of 
the studies included in the meta- analysis were hospital- 
based studies (60%) that used non- random sampling 
procedures (80%). Therefore, population- based studies 
are warranted. Finally, we found substantial heterogeneity 
between the studies and conducted meta- regression anal-
ysis, which did not explain the heterogeneity. The lack 
of uniformity and variance in the blood pressure cut- off 
points for the different comorbidities may have resulted 
in this heterogeneity.
CONCLUSION
In conclusion, the prevalence of UHTN is high in people 
with comorbid conditions in SSA, particularly among 
people with diabetes. These findings strengthen the case 
for action to implement integrated care in the control of 
hypertension more effectively in African populations and 
other low- income and middle- income countries. Such 
efforts include improved access to blood pressure testing 
among people with comorbidities, strategies to improve 
adherence, reviewing treatment guidelines and training 
of healthcare workers in managing people with hyper-
tension comorbidities and monitoring blood pressure 
control among all patients on treatment.
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